Latest News - Retina

Thursday, January 04, 2018 | Retina, Pixium Vision

Pixium Vision Receives FDA Approval to Begin Human Clinical Study of Its PRIMA Retinal Implant in the US

Pixium Vision announced that it has received approval from the FDA to begin the clinical feasibility study for PRIMA, Pixium Vision’s new-generation miniaturized wireless photovoltaic subretinal…

Read the full story

Wednesday, December 20, 2017 | Retina

Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform

Ocugen announced a strategic expansion to its leading ophthalmology product development pipeline that enhances the company's focus on inherited retinal disorders (IRDs). Ocugen has obtained an exc…

Read the full story

Monday, December 18, 2017 | Clinical Trials, Retina, SciFluor Life Sciences

SciFluor Announces Positive Topline Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet AMD

SciFluor Life Sciences announced positive topline results of a phase 1/2 trial studying the treatment of wet age-related macular degeneration (AMD) patients with SF0166, the company’s lead eye d…

Read the full story

Monday, December 11, 2017 | Retina, Regeneron Pharmaceuticals

Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of Eylea (aflibercept) for Patients with Wet AMD

Regeneron announced that the FDA has accepted for review the company's supplemental Biologics License Application for a 12-week dosing interval of Eylea (aflibercept) injection in patients with we…

Read the full story

Tuesday, December 05, 2017 | Blindness, Retina, Second Sight Medical Products

Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal Prosthesis System

Second Sight Medical Products announced market entry into Iran, implanting the first two patients with the company’s Argus II Retinal Prosthesis System. The implant was facilitated by the countr…

Read the full story

Friday, November 17, 2017 | Product Releases, Retina

Vortex Surgical Launches Innovative Convenience Kits

Vortex Surgical announced the release of the Vortex Surgical Convenience Kit. Launched during the annual meeting of the American Academy of Ophthalmology in New Orleans, the product is targeted a…

Read the full story

Monday, November 13, 2017 | Retina, Genentech

Genentech Makes Statement Following Release of Novartis' Brolucizumab Data

At the American Academy of Ophthalmology meeting in New Orleans, Novartis announced positive results from two phase 3 studies (HAWK and HARRIER) of brolucizumab versus Regeneron's aflibercept (Eyl…

Read the full story

Monday, November 13, 2017 | Clinical Trials, Retina, Novartis

Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity in nAMD

Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiority in primary endpoint, superiority in key retinal health ou…

Read the full story

Friday, November 10, 2017 | Clinical Trials, Retina, Spark Therapeutics

Three-year Follow-up Phase 3 Data Provide Additional Information on Luxturna in Patients with Biallelic RPE65-Mediated Inherited Retinal Disease

Spark Therapeutics announced new 3-year follow-up data from the continuing phase 3 trial of Luxturna (voretigene neparvovec), an investigational, potential one-time gene therapy for the treatment of p…

Read the full story

Wednesday, November 08, 2017 | Product Releases, Retina, OD-OS GmbH

OD-OS Announces New Framework for Remote Planning of Navigated Retinal Laser Treatments

OD-OS announced the upcoming release of NaviGATE - a new framework for remote planning of retinal treatments with the Navilas 577s navigated laser system. NaviGATE allows physicians to digitally pre-p…

Read the full story

Tuesday, November 07, 2017 | Conferences, Retina, Novartis

Novartis Pivotal Brolucizumab (RTH258) Data to be Presented at AAO

Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for the treatment of neovascular age-related macular degeneration…

Read the full story

Monday, October 30, 2017 | Product Releases, Retina, Allergan

Allergan Receives Approval for Ozurdex in China for the Treatment of Retinal Vein Occlusion

Allergan announced that it has received an imported drugs license from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment o…

Read the full story

Friday, October 27, 2017 | Retina

Lin BioScience Receives FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease

Lin BioScience announced that the FDA has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is caused by a mutation…

Read the full story

Wednesday, October 25, 2017 | Clinical Trials, Retina, Clearside Biomedical

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with DME

Clearside Biomedical announced completion of patient enrollment in the phase 2 clinical trial (TYBEE) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolon…

Read the full story

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story
Load More